Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, ...

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

A Series in The Lancet Neurology provides state-of-the-art reviews covering clinical and scientific evidence on the four most common genetic subtypes of amyotrophic lateral sclerosis (ALS), caused by ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.